SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb amid reported Middle East shipping and energy-infrastructure attacks, fueling concerns about supply disruptions. Traders are divided between expecting the supply-risk rally to continue and anticipating a pullback if tensions ease; some also caution that the expiring WTI contract can distort comparisons with the next contract.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is under pressure after HSBC warned that heavy borrowing needs and potentially slower AI-compute demand could challenge its growth and returns, sharpening traders concerns about debt, refinancing, and dilution amid a broader neocloud selloff. Bears warn of credit and business-model risks, while bulls point to contracted demand and continued AI infrastructure growth; some also cite Goldman Sachss more positive view and ARKs share purchases.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares have slid to post-IPO lows amid concern over insider selling and successive lockup share releases, with traders also pointing to a TD Cowen price-target cut and questions about growth, scaling, and reliance on OpenAI. The discussion is sharply divided between calls for more downside and buyers arguing the selloff is overdone and the AI-chip technology has long-term potential.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock, citing long commercialization timelines and limited firm customer commitments, with uncertainty around the proposed TVA deployment adding to execution concerns. Traders are split between viewing the selloff as an overreaction and seeing it as confirmation of risks facing NuScale and the broader nuclear sector.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound after the recent selloff, ahead of major megacap earnings, is driving QQQ discussion. Traders are divided over whether it marks a durable recovery or a relief rally that could fade, with AI investment and debt concerns and surging oil prices adding to caution.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces third-quarter earnings beat and raised 2026 guidance are driving attention, with traders also citing stronger orders. Many view the report as bullish, while others are cautious about whether the stock can hold its post-earnings strength amid muted or weakening price action.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings and revenue beat estimates, but traders are focused on the tightened full-year profit outlook rather than a larger guidance increase. The new buyback program is a positive offset for some, while others question why shares are falling despite the beat.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrops Q3 results beat expectations and management raised its full-year outlook, with a record backlog reinforcing the growth case. Traders are debating why shares remain under pressure despite the strong report, pointing to margin and cash-flow concerns and the possibility that the positive news was already priced in.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples iPhone Duo preorders reportedly sold out quickly, with deliveries pushed out, drawing bullish attention to demand and the stocks resilience while AI and semiconductor shares faced pressure. Skeptics counter that limited launch supply may explain the sellout and question whether the premium-priced phone will drive meaningful incremental sales, amid broader concerns about Apples valuation.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius has been caught in a sharp neocloud and AI-infrastructure selloff as traders debate whether heavy buildout spending can earn adequate returns and whether financing risksespecially at CoreWeavewill spread across the sector. The community is split between treating the rebound after the decline as an oversold bounce and expecting more downside, while some argue Nebius is better positioned than debt-heavier peers and that compute demand remains strong.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long

Equity

The FDA has told Novo that its review of the biologics license application is still underway and has not given a new date for a decision.

NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip

NVO stock is down 11% this week, on track for its worst week since late February if losses hold. 


NVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia Pen 

The Committee for Medicinal Products for Human Use recommended European Union marketing authorization for Frehemgo in adults and children with haemophilia A on Thursday.


AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus 

A combination of the company’s breast cancer drug Etcamah did not delay worsening of the disease enough to meet the SERENA-4 late-stage trial’s main goal, AstraZeneca said. 


Want to Tap Global Growth? These Equity ETFs Could Benefit

Seeking growth beyond U.S. borders? Global equity ETFs could offer diversification and exposure to attractive opportunities across international markets.

NVO Stock Drops 6% Despite Raised Guidance As Investors Worry About Injectable GLP-1 Sales Future

Novo now expects underlying sales and operating profit in the range of 0% to –6% for the year.

NVO Stock Ends Three-Month Winning Streak As Novo Nordisk’s Key Heart Drug Flops, Competition Goes To Court

The Danish drugmaker reported on Friday that its experimental cardiovascular drug ziltivekimab failed a key late-stage trial, marking a significant pipeline setback in its efforts to diversify beyond blockbuster obesity and diabetes treatments.


Global ETFs to Diversify as Tech Weakness Weighs on Markets

The AI trade is under pressure as a semiconductor slump and financing concerns rattle markets, making global ETFs worth a closer look.

NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart

Oral Wegovy is now cleared in all EU member states.


Global ETFs Back in the Spotlight on Macroeconomic Tailwinds

Easing geopolitical tensions, a softer dollar and improving risk appetite are reviving interest in global equity ETFs.

American Century ETF Trust - Avantis International Equity ETF

Bullish Sentiment

<ul class="summary-bullets"><li>Novo said the agency extended the review because remediation at the facility is still ongoing.</li><li>The company said the longer review does not change its 2026 financial outlook.</li><li>Novo’s rare blood-disorders sales were about DKK 12.0 billion in 2025, against group sales of DKK 309 billion.</li></ul><p>Danish drugmaker Novo Nordisk (NVO) said on Friday that U.S. approval of its haemophilia A drug denecimig will slip past the third quarter because fixes at a manufacturing site are still underway.&nbsp;</p><p>The FDA has told Novo that its review of the biologics license application is still underway and has not provided a new decision date. Novo filed the application in September 2025 for adults and children with haemophilia A, with or without inhibitors, and had expected a ruling in the third quarter of 2026.</p><h2 class="st-heading-2">A Plant Issue, Not A Clinical One, Says Novo</h2><p>The delay follows a pre-license inspection of the manufacturing site. Novo said the agency extended the review because remediation at the facility is still ongoing. The company said it is already addressing the requests and working with the FDA on the remaining items. It also said the inspection feedback does not affect other marketed Novo products, and that the agency has not flagged deficiencies in the clinical efficacy or safety data in the filing.</p><p>Novo said the longer review does not change its 2026 financial outlook. It now aims to launch denecimig in the United States in the first half of 2027, pending a decision.</p><p>Novo’s rare blood-disorders sales were about DKK 12.0 billion in 2025, against group sales of DKK 309 billion. Obesity care alone was DKK 82 billion. Outside analysts have put denecimig’s peak sales near $2 billion a year. Roche’s Hemlibra, the drug it would have to take share from, did about $5.8 billion last year.</p><h2 class="st-heading-2">What The Drug Is Meant To Do</h2><p>Denecimig is a bispecific antibody designed to mimic factor VIIIa, the clotting protein missing or defective in haemophilia A.&nbsp; Novo is seeking approval for prophylaxis — treatment meant to prevent bleeds — on a monthly, every-two-week, or weekly schedule, including in patients who have developed inhibitors to standard factor replacement.</p><p>The filing rests on the FRONTIER program. FRONTIER2 tested weekly and monthly dosing in adults and adolescents 12 and older. FRONTIER3 did the same in children under 12. FRONTIER4, an open-label extension, looked at every-two-week dosing and longer-term safety across all three schedules.&nbsp;</p><p>On Sept. 17, denecimig received a positive opinion from the European Medicines Agency’s human medicines committee and is now also awaiting a European Commission decision.</p><h2 class="st-heading-2">How Did NVO Retail Traders React?</h2><p>On Stocktwits, retail sentiment around <a class="mention" data-mention="$NVO" data-symbol-id="NVO" href="https://stocktwits.com/symbol/NVO" target="_blank">NVO stock</a> stayed neutral over the past 24 hours, while message volume remained low.&nbsp;</p><p>NVO stock has fallen 27% year-to-date.&nbsp;</p><p>Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-climbs-as-three-thursday-launches-meet-start-of-google-s-920-million-ai-pact/cZDjn9cRBKN">SPCX Stock Climbs As Three Thursday Launches Meet Start Of Google’s $920 Million AI Pact</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk A/S

VanEck Pharmaceutical ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Feed

News

Sentiment

Fundamentals

Info

AVDE American Century ETF Trust - Avantis International Equity ETF

Fundamentals

Latest AVDE News